Ondansetron
Nodal Marginal Zone B-Cell Lymphoma
Explore 35 assets in Nodal Marginal Zone B-Cell Lymphoma →Floatz Rating
B60/100
Confidence
Indicative
Sponsor
UNC Lineberger Comprehensive Cancer Center
Modality
Small molecule
Development Phase
Phase 2
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
48Moderate confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT04223765CT.gov Study of Kappa Chimeric Antigen Receptor (CAR) T Lymphocytes Co-Expressing the Kappa and CD28 CARs for Relapsed/Refractory Kappa+ Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma. | — | Recruiting | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
81High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Nodal Marginal Zone B-Cell Lymphoma
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Ondansetron (this asset) | UNC Lineberger Comprehensive Cancer Center | P2 | B · 60 |
| Cyclophosphamide | SWOG Cancer Research Network | P2 | BB |
| Etoposide | University of California, Davis | P2 | BB |
| Fludarabine | UNC Lineberger Comprehensive Cancer Center | P2 | BB |
| Dexasone | Izidore Lossos, MD | P2 | BB |
| Romidepsin | Mayo Clinic | P2 | BB |
| Cyclosporin A | National Cancer Institute (NCI) | P2 | BB |
| Cediranib | National Cancer Institute (NCI) | P2 | BB |
| Rituximab | City of Hope Medical Center | P3 | BB |
+42 more in the Nodal Marginal Zone B-Cell Lymphoma cohort
Other indications for Ondansetron
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Cancer Of Unknown Primary Site | — | P3 | BB · 71 |
| Childhood Neoplasm | — | P3 | BB · 66 |
| Alcohol Abuse | — | P4 | BB · 66 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Ondansetron in Nodal Marginal Zone B-Cell Lymphoma. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/ondansetron-nodal-marginal-zone-b-cell-lymphoma
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →